A Biotech ETF for Up-and-Coming Drug Developers
September 5th, 2013 at 2:17pm by Tom Lydon
I do the “ETF of the Week” for MarketWatch every Thursday on Chuck Jaffe’s MoneyLife Show where I highlight big movers and disappointments within the exchange traded fund market.
This Thursday, I took a look at the SPDR S&P Biotech ETF (NYSEArca: XBI). Instead of betting on a few small up-and-coming biotechnology firms, this equal-weight biotech ETF helps provide a diversified approach to the industry.
Click here to listen to the podcast.
To access previous podcasts, take a look at our podcasts category.
The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.